These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 11241416

  • 1. Chondrosarcoma is not characterized by detectable telomerase activity.
    Bovée JV, van Den Broek LJ, Cleton-Jansen AM, Hogendoorn PC.
    J Pathol; 2001 Mar; 193(3):354-60. PubMed ID: 11241416
    [Abstract] [Full Text] [Related]

  • 2. Malignant transformation in human chondrosarcoma cells supported by telomerase activation and tumor suppressor inactivation.
    Martin JA, Forest E, Block JA, Klingelhutz AJ, Whited B, Gitelis S, Wilkey A, Buckwalter JA.
    Cell Growth Differ; 2002 Sep; 13(9):397-407. PubMed ID: 12354749
    [Abstract] [Full Text] [Related]

  • 3. D2-40 functions as an effective chondroid marker distinguishing true chondroid tumors from chordoma.
    Huse JT, Pasha TL, Zhang PJ.
    Acta Neuropathol; 2007 Jan; 113(1):87-94. PubMed ID: 17021752
    [Abstract] [Full Text] [Related]

  • 4. Selective increase in expression of isoform PP1 gamma 1 of type-1 protein phosphatase in chondrosarcoma cells.
    Sogawa K, Yamada T, Funamoto Y, Kohno K, Nishikawa H, Kishida F, Hamazaki F, Yamashita N, Matsumoto K.
    Res Commun Mol Pathol Pharmacol; 1994 Dec; 86(3):375-8. PubMed ID: 7712113
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma.
    Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K, Yamamoto H, Tsuchiya H.
    Cancer; 2007 Jun 15; 109(12):2532-40. PubMed ID: 17497647
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis and prognosis of chondrosarcoma of bone.
    Rozeman LB, Hogendoorn PC, Bovée JV.
    Expert Rev Mol Diagn; 2002 Sep 15; 2(5):461-72. PubMed ID: 12271817
    [Abstract] [Full Text] [Related]

  • 8. [Benign cartilaginous tumors].
    Erlemann R.
    Radiologe; 2001 Jul 15; 41(7):548-59. PubMed ID: 11490775
    [Abstract] [Full Text] [Related]

  • 9. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas.
    Rozeman LB, Hameetman L, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovée JV.
    J Pathol; 2005 Mar 15; 205(4):476-82. PubMed ID: 15685701
    [Abstract] [Full Text] [Related]

  • 10. Assessment of interobserver variability and histologic parameters to improve reliability in classification and grading of central cartilaginous tumors.
    Eefting D, Schrage YM, Geirnaerdt MJ, Le Cessie S, Taminiau AH, Bovée JV, Hogendoorn PC, EuroBoNeT consortium.
    Am J Surg Pathol; 2009 Jan 15; 33(1):50-7. PubMed ID: 18852676
    [Abstract] [Full Text] [Related]

  • 11. Cartilaginous bone tumors.
    Giudici MA, Moser RP, Kransdorf MJ.
    Radiol Clin North Am; 1993 Mar 15; 31(2):237-59. PubMed ID: 8446748
    [Abstract] [Full Text] [Related]

  • 12. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade.
    Rozeman LB, Hameetman L, van Wezel T, Taminiau AH, Cleton-Jansen AM, Hogendoorn PC, Bovée JV.
    J Pathol; 2005 Sep 15; 207(1):61-71. PubMed ID: 16007578
    [Abstract] [Full Text] [Related]

  • 13. What are the differentiating clinical and MRI-features of enchondromas from low-grade chondrosarcomas?
    Douis H, Parry M, Vaiyapuri S, Davies AM.
    Eur Radiol; 2018 Jan 15; 28(1):398-409. PubMed ID: 28695356
    [Abstract] [Full Text] [Related]

  • 14. Minichromosome maintenance protein (MCM6) in low-grade chondrosarcoma: distinction from enchondroma and identification of progressive tumors.
    Helfenstein A, Frahm SO, Krams M, Drescher W, Parwaresch R, Hassenpflug J.
    Am J Clin Pathol; 2004 Dec 15; 122(6):912-8. PubMed ID: 15539383
    [Abstract] [Full Text] [Related]

  • 15. Telomerase activity and its inhibition in benign and malignant breast lesions.
    Sugino T, Yoshida K, Bolodeoku J, Tarin D, Goodison S.
    J Pathol; 1997 Sep 15; 183(1):57-61. PubMed ID: 9370948
    [Abstract] [Full Text] [Related]

  • 16. [The value of CT and MRT in the diagnosis of cartilage-forming tumors].
    Reuther G, Mutschler W.
    Rofo; 1989 Dec 15; 151(6):647-52. PubMed ID: 2556737
    [Abstract] [Full Text] [Related]

  • 17. Telomerase activity in phyllodes tumours.
    Mokbel K, Ghilchik M, Parris CN, Newbold RF.
    Eur J Surg Oncol; 1999 Aug 15; 25(4):352-5. PubMed ID: 10419703
    [Abstract] [Full Text] [Related]

  • 18. Prognostic relevance of cell biologic and biochemical features in conventional chondrosarcomas.
    Aigner T, Müller S, Neureiter D, Illstrup DM, Kirchner T, Björnsson J.
    Cancer; 2002 Apr 15; 94(8):2273-81. PubMed ID: 12001127
    [Abstract] [Full Text] [Related]

  • 19. The clinical approach towards chondrosarcoma.
    Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, Bovée JV.
    Oncologist; 2008 Mar 15; 13(3):320-9. PubMed ID: 18378543
    [Abstract] [Full Text] [Related]

  • 20. PAS inclusions, immunoreactive tenascin and proliferative activity in low-grade chondrosarcomas.
    Ranty ML, Michot C, Le Pessot F, Hellot MF, Biga N, Dujardin FH, Simonet J, Billerey C, Metayer J.
    Pathol Res Pract; 2003 Mar 15; 199(1):29-34. PubMed ID: 12650515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.